Corporate Update on Genmab and AbbVie’s Epcoritamab Phase 3 Trial Results
Genmab A/S and AbbVie Inc. have disclosed that the U.S. arm of the Phase 3 EPCORE DLBCL‑1 trial, which evaluated the bispecific antibody epcoritamab in adults with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival (OS). The data were presented in a poster session at the recent European Hematology Association (EHA) congress and are being prepared for publication in a peer‑reviewed journal.
Study Design and Primary Endpoint
The EPCORE DLBCL‑1 trial was a randomized, open‑label, multi‑center investigation comparing subcutaneous epcoritamab with investigator‑selected chemo‑immunotherapy (CIT) in patients who had experienced disease relapse or refractoriness after at least one prior systemic therapy. The primary efficacy endpoint differed by region:
| Region | Primary Endpoint |
|---|---|
| United States | Overall survival (OS) |
| Europe, Canada, other regions | Investigator‑chosen endpoint (e.g., event‑free survival or progression‑free survival) |
The U.S. cohort comprised 250 participants, with a median follow‑up of 18 months. The trial’s design aimed to detect a hazard ratio (HR) of 0.75 for OS, corresponding to a 25 % reduction in the risk of death with epcoritamab versus CIT.
Key Findings
- Overall Survival: The observed median OS was 22.3 months for epcoritamab versus 20.1 months for CIT. The hazard ratio was 0.92 (95 % CI: 0.76–1.11; p = 0.34), indicating no statistically significant improvement in survival in the U.S. population.
- Secondary Endpoints: Across all regions, epcoritamab demonstrated a higher overall response rate (ORR) of 48 % versus 31 % for CIT, and a median duration of response (DoR) of 14.7 months versus 9.4 months. However, these benefits did not translate into a statistically significant OS advantage within the U.S. cohort.
- Safety Profile: Treatment‑emergent adverse events (TEAEs) were consistent with the known safety profile of bispecific antibodies. The most frequent grade ≥ 3 events were hematologic cytopenias (neutropenia, thrombocytopenia) and cytokine release syndrome (CRS) of grade 1‑2 severity. Serious adverse events (SAEs) occurred in 12 % of patients receiving epcoritamab versus 9 % in the CIT arm.
Regulatory and Commercial Implications
- Regulatory Pathways: The failure to meet the U.S. primary endpoint necessitates a careful review of the trial data by the U.S. Food and Drug Administration (FDA). While the European Medicines Agency (EMA) and other regulatory bodies may consider the non‑OS endpoints for approval decisions, the U.S. approval pathway could be delayed or require additional evidence, such as post‑marketing studies or expanded indications.
- Operational Impact: Both companies reported no immediate operational or commercial changes. The continuation of ongoing studies, including Phase 2 trials in earlier lines of therapy and combination regimens, is emphasized.
- Strategic Outlook: Genmab and AbbVie reaffirmed their commitment to further evaluation of epcoritamab in other disease settings, including follicular lymphoma and multiple myeloma, as well as exploring combination strategies with checkpoint inhibitors or targeted agents.
Practical Considerations for Healthcare Professionals
- Patient Selection: Given the absence of an OS benefit in the U.S. cohort, clinicians should carefully weigh the therapeutic advantages of epcoritamab, particularly its superior ORR and DoR, against the potential risks and the lack of confirmed survival benefit in this population.
- Safety Management: Vigilant monitoring for CRS and cytopenias remains essential. Pre‑medication protocols, dose‑escalation schedules, and early intervention strategies should be reinforced based on the current safety data.
- Insurance Coverage: Payers may adopt a more cautious stance regarding reimbursement for epcoritamab in relapsed or refractory DLBCL until more definitive efficacy data, especially in the U.S. setting, are available.
Conclusion
The Phase 3 EPCORE DLBCL‑1 trial results underscore the complexity of translating promising early‑phase findings into clinically meaningful survival benefits. While epcoritamab shows encouraging activity and a manageable safety profile, the lack of an OS advantage in the U.S. cohort presents regulatory and commercial challenges. Continued analysis of the full dataset and exploration of alternative therapeutic contexts will be critical for determining epcoritamab’s future role in lymphoma treatment.
